223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

223.6

+3.09%↑

MRK1

153.55

-0.71%↓

SHL.DE

48.11

-0.35%↓

UCB

178.7

-0.97%↓

ARGX

544.2

-1.13%↓

Inicio・Lista de Acciones・Sanofi SA

Sanofi SA

Cerrado

Sector Salud

97.74 -0.91

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

97.6

Máximo

99.11

Métricas clave
By Trading Economics
Ingresos	1.7B 2.8B
Ventas	2.1B 13B
P/B Media del Sector	30.62 104.138
BPA	2.86
Margen de beneficio	20.945
EBITDA	2.2B 4.2B

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+13.81 upside

Dividendos
By Dow Jones
Próximas Ganancias	30 ene 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	123B
Apertura anterior	98.65
Cierre anterior	97.74

Noticias sobre sentimiento de mercado

By Acuity

58%

42%

313 / 390 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

98.41 / 99.5 Soporte y Resistencia

Sanofi SA Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

29 oct 2024, 10:07 UTC

Ganancias

Santander's Profit Beats Expectations on Lower Provisions, Costs -- Update

29 oct 2024, 06:37 UTC

Ganancias

Santander's Profit Beats View Despite Lower-Than-Expected Revenue

28 oct 2024, 16:07 UTC

Adquisiciones, fusiones, absorciones

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion -- Update

25 oct 2024, 05:44 UTC

Ganancias

Sanofi Profit, Sales Beat Estimates

29 oct 2024, 13:16 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Conditions Lack for Attractive European Cross-Border M&A Deals, Santander CEO Says -- Market Talk

29 oct 2024, 07:02 UTC

Charlas de Mercado

Santander's Take on Brazil Rates, Motor-Finance Issue in Focus -- Market Talk

29 oct 2024, 05:52 UTC

Ganancias

Santander Backs 2024 View

29 oct 2024, 05:52 UTC

Ganancias

Santander: If All Targets Are Met, Total Remuneration Against 2024 Results Over EUR6B

29 oct 2024, 05:51 UTC

Ganancias

Santander Confident on Delivering on Targets

29 oct 2024, 05:50 UTC

Ganancias

Analysts Saw Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct 2024, 05:50 UTC

Ganancias

Santander End-3Q Fully Loaded CET1 Ratio 12.5%

29 oct 2024, 05:49 UTC

Ganancias

Analyst Saw Santander 3Q Net Interest Income EUR11.59B

29 oct 2024, 05:49 UTC

Ganancias

Santander 3Q Net Interest Income EUR11.225B

29 oct 2024, 05:48 UTC

Ganancias

Analysts Saw Santander 3Q Net Loan Loss Provisions EUR3.17B

29 oct 2024, 05:48 UTC

Ganancias

Santander 3Q Net Loan Loss Provisions EUR2.98B

29 oct 2024, 05:48 UTC

Ganancias

Analysts Saw Santander 3Q Net Pft EUR3.17B

29 oct 2024, 05:48 UTC

Ganancias

Santander 3Q Net Pft EUR3.25B

29 oct 2024, 05:48 UTC

Ganancias

Santander 3Q Rev EUR15.135B

29 oct 2024, 05:48 UTC

Ganancias

Analysts Saw Santander 3Q Rev EUR15.31B

28 oct 2024, 08:18 UTC

Charlas de Mercado

Banks' Risks From U.K. Motor Finance Probe Rise -- Market Talk

25 oct 2024, 20:25 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct 2024, 13:12 UTC

Ganancias

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat -- IBD

25 oct 2024, 07:00 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Sanofi's 3Q Results Show Solid Vaccine Performance -- Market Talk

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Adj EPS EUR2.86

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q FCF EUR3.33B

25 oct 2024, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Business Operating Income at EUR4.03B

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Business Net Profit EUR3.59B

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Sales EUR13.44B

25 oct 2024, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Sales at EUR12.63B

25 oct 2024, 05:30 UTC

Ganancias

Sanofi 3Q Business Operating Profit EUR4.61B

Comparación entre iguales

Cambio de precio

Sanofi SA Esperado

Precio Objetivo

By TipRanks

13.81% repunte

Estimación a 12 meses

Media 112.331 EUR 13.81%

Máximo 130 EUR

Mínimo 90 EUR

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para Sanofi SA Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

98.41 / 99.5Soporte y Resistencia

Recent bearish events outweigh bullish events.

All events are bullish.

Sentimiento

By Acuity

313 / 390 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Sanofi SA

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.